OBJECTIVE: To model the effect of adherence and duration of viral suppression on the risk of viral rebound. METHODS: Viral rebound was defined as the first of at least two consecutive viral loads greater than 400 copies/mL after initial viral suppression. The main exposures were adherence, presence of antiretroviral class resistance before rebound or censoring date, and the percentage of follow-up time with viral suppression. RESULTS: A total of 274 (N = 1305 [21%]) individuals experienced viral rebound. Median time of suppression before rebound was 2 years. Viral rebound was less likely to occur among those with longer duration of continuous viral suppression (odds ratio, 0.37; 95% confidence interval, 0.32 to 0.42). Among individuals with moderate levels of adherence (80% to less than 95%), the probability of virologic failure was 0.85 after being suppressed for 12 months and it was 0.08 after 72 months being suppressed (P < 0.01). Individuals with drug resistance were at a higher risk of viral rebound. CONCLUSIONS: The risk of viral rebound decreased with longer duration of viral suppression within each of adherence strata studied. Although perfect adherence remains an important goal of therapy to prevent disease progression, individuals with long-term viral suppression may be able to miss more doses without experiencing viral rebound.
OBJECTIVE: To model the effect of adherence and duration of viral suppression on the risk of viral rebound. METHODS: Viral rebound was defined as the first of at least two consecutive viral loads greater than 400 copies/mL after initial viral suppression. The main exposures were adherence, presence of antiretroviral class resistance before rebound or censoring date, and the percentage of follow-up time with viral suppression. RESULTS: A total of 274 (N = 1305 [21%]) individuals experienced viral rebound. Median time of suppression before rebound was 2 years. Viral rebound was less likely to occur among those with longer duration of continuous viral suppression (odds ratio, 0.37; 95% confidence interval, 0.32 to 0.42). Among individuals with moderate levels of adherence (80% to less than 95%), the probability of virologic failure was 0.85 after being suppressed for 12 months and it was 0.08 after 72 months being suppressed (P < 0.01). Individuals with drug resistance were at a higher risk of viral rebound. CONCLUSIONS: The risk of viral rebound decreased with longer duration of viral suppression within each of adherence strata studied. Although perfect adherence remains an important goal of therapy to prevent disease progression, individuals with long-term viral suppression may be able to miss more doses without experiencing viral rebound.
Authors: Kersten K Koelsch; Lin Liu; Richard Haubrich; Susanne May; Diane Havlir; Huldrych F Günthard; Caroline C Ignacio; Paula Campos-Soto; Susan J Little; Robert Shafer; Gregory K Robbins; Richard T D'Aquila; Yuji Kawano; Karen Young; Phillip Dao; Celsa A Spina; Douglas D Richman; Joseph K Wong Journal: J Infect Dis Date: 2008-02-01 Impact factor: 5.226
Authors: Viviane D Lima; Vikram S Gill; Benita Yip; Robert S Hogg; Julio S G Montaner; P Richard Harrigan Journal: J Infect Dis Date: 2008-07-01 Impact factor: 5.226
Authors: M R Furtado; D S Callaway; J P Phair; K J Kunstman; J L Stanton; C A Macken; A S Perelson; S M Wolinsky Journal: N Engl J Med Date: 1999-05-27 Impact factor: 91.245
Authors: J S Montaner; P Reiss; D Cooper; S Vella; M Harris; B Conway; M A Wainberg; D Smith; P Robinson; D Hall; M Myers; J M Lange Journal: JAMA Date: 1998-03-25 Impact factor: 56.272
Authors: Scott M Hammer; Michael S Saag; Mauro Schechter; Julio S G Montaner; Robert T Schooley; Donna M Jacobsen; Melanie A Thompson; Charles C J Carpenter; Margaret A Fischl; Brian G Gazzard; Jose M Gatell; Martin S Hirsch; David A Katzenstein; Douglas D Richman; Stefano Vella; Patrick G Yeni; Paul A Volberding Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: R M Gulick; J W Mellors; D Havlir; J J Eron; C Gonzalez; D McMahon; D D Richman; F T Valentine; L Jonas; A Meibohm; E A Emini; J A Chodakewitz Journal: N Engl J Med Date: 1997-09-11 Impact factor: 91.245
Authors: Tae-Wook Chun; J Shawn Justement; Susan Moir; Claire W Hallahan; Janine Maenza; James I Mullins; Ann C Collier; Lawrence Corey; Anthony S Fauci Journal: J Infect Dis Date: 2007-05-02 Impact factor: 5.226
Authors: Sarah Palmer; Frank Maldarelli; Ann Wiegand; Barry Bernstein; George J Hanna; Scott C Brun; Dale J Kempf; John W Mellors; John M Coffin; Martin S King Journal: Proc Natl Acad Sci U S A Date: 2008-03-10 Impact factor: 11.205
Authors: D William Cameron; Barbara A da Silva; Jose R Arribas; Robert A Myers; Nicholaos C Bellos; Norbert Gilmore; Martin S King; Barry M Bernstein; Scott C Brun; George J Hanna Journal: J Infect Dis Date: 2008-07-15 Impact factor: 5.226
Authors: Woldesellassie M Bezabhe; Luke R Bereznicki; Leanne Chalmers; Peter Gee; Desalew M Kassie; Mekides A Bimirew; Gregory M Peterson Journal: Drug Saf Date: 2015-10 Impact factor: 5.606
Authors: L Lourenço; H Samji; A Nohpal; W Chau; G Colley; K Lepik; R Barrios; V Lima; R S Hogg; Jsg Montaner; S Kesselring; D M Moore Journal: HIV Med Date: 2015-02-27 Impact factor: 3.180
Authors: Susan M Graham; Zahra Jalalian-Lechak; Juma Shafi; Vrasha Chohan; Ruth W Deya; Walter Jaoko; Kishor N Mandaliya; Norbert M Peshu; Julie Overbaugh; R Scott McClelland Journal: J Acquir Immune Defic Syndr Date: 2012-08-15 Impact factor: 3.731
Authors: Jose R Castillo-Mancilla; Todd T Brown; Kristine M Erlandson; Frank J Palella; Edward M Gardner; Bernard J C Macatangay; Elizabeth C Breen; Lisa P Jacobson; Peter L Anderson; Nikolas I Wada Journal: Clin Infect Dis Date: 2016-09-22 Impact factor: 9.079
Authors: Kathleen N Deering; Tara Lyons; Cindy X Feng; Bohdan Nosyk; Steffanie A Strathdee; Julio S G Montaner; Kate Shannon Journal: J Acquir Immune Defic Syndr Date: 2013-08-01 Impact factor: 3.731